People: Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

7 Aug 2020
Change (% chg)

$-3.71 (-4.10%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Stenhouse, Mark 

Mr. Mark Stenhouse serves as General Manager - Screening of the Company. Mr. Stenhouse has served as President, Cologuard since April 2018. Prior to joining Exact, Mr. Stenhouse worked for over 25 years at Abbott Laboratories (NYSE: ABT) and AbbVie, Inc. (NYSE: ABVV), including in a number of executive and managerial positions within its U.S. Immunology division. Most recently, from October 2016 until March 2018, Mr. Stenhouse served as Vice President, U.S. Immunology, where Mr. Stenhouse developed AbbVie's U.S. expansion into the immunology marketplace. From April 2010 until September 2016, Mr. Stenhouse served as Vice President and Vice President/General Manager, U.S. Immunology—Gastroenterology Franchise, where Mr. Stenhouse led a successful turnaround of the franchise, including approval of HUMIRA for treatment of Ulcerative Colitis. From September 2006 through March 2010, Mr. Stenhouse held various senior management, marketing and sales positions within Abbott Laboratories' U.S. Immunology division. Mr. Stenhouse earned a bachelor's degree in business administration from College of Charleston.

Basic Compensation

Total Annual Compensation, USD 1,191,350
Restricted Stock Award, USD 3,708,410
Long-Term Incentive Plans, USD --
All Other, USD 645,292
Fiscal Year Total, USD 5,545,050

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Kevin Conroy


Jeffrey Elliott


D. Scott Coward


Graham Lidgard


Ana Hooker


Scott Johnson

As Of  31 Dec 2019